Methyl (Αs,3S)-Α-[[(1,1-Dimethylethoxy)Carbonyl]Amino]-2-Oxo-3-Pyrrolidinepropanoate

The synthesis of reversible covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) main protease (M^pro, also referred to as 3CL^pro) frequently relies on conformationally constrained P2–P3 mimetics to displace the native substrate recognition sequence. The (3S,αS)-α-[[(1,1-dimethylethoxy)carbonyl]amino]-2-oxo-3-pyrrolidinepropanoate scaffold serves as a β-homoprolinate isostere that pre-organizes the ψ-dihedral angle, reducing the entropic penalty associated with binding to the S2 subsite. Regulatory oversight for such advanced starting materials falls under ICH Q11 (Development and Manufacture of Drug Substances) and the FDA 21 CFR Part 210/211 cGMP framework when the pyrrolidinone fragment is classified as a regulatory starting material (RSM) by a holder of a US Type II DMF. In process chemistry for a typical amide coupling step with a pyrazinone or pyrrolidone-based P1 element, the stoichiometric ratio is maintained at 1.10 – 1.25 molar equivalents relative to the limiting P1 amine, charged in a single portion at –5 °C to suppress epimerization at the α-carbon while activation is achieved with 2‑propanephosphonic acid anhydride (T3P, 1.5 eq) and collidine (3.0 eq) in anhydrous tetrahydrofuran. The downstream manufacturing protocol requires a controlled single-step Boc‑deprotection using a pre‑cooled mixture of trifluoroacetic acid and dichloromethane (30:70 v/v) over a proscribed residence time of 15 minutes at 0 °C, followed by vacuum distillation under reduced pressure (≤ 50 mbar) with residual TFA content monitored by ion chromatography to remain below 50 ppm. The terminal finished product is an oral SARS‑CoV‑2 3CL protease inhibitor, formulated as a co‑dosage with ritonavir (300 mg/100 mg daily split dose), designed to achieve sustained systemic exposure in human subjects.

Why a (3S)-lactam P2 moiety outperforms conventional proline in pan‑genotypic HCV NS3/4A inhibitors

Structural biology studies on the hepatitis C virus NS3/4A serine protease have established that oxidation of the pyrrolidine ring of proline to a γ‑lactam introduces a hydrogen‑bond acceptor that engages the catalytic His57 residue or the oxyanion‑stabilizing amide backbone within the S2 pocket, thereby increasing inhibitory capacity against genotype 3a replicons with Q80K polymorphisms. Compliance with pharmacopoeial monographs requires that residual palladium originating from coupling catalysts be controlled according to ICH Q3D Elemental Impurities Guidance (Class 2A elements, maximum permitted daily exposure of 100 µg/day), while residual solvents are validated against ICH Q3C(R9) Table 2 limits for dichloromethane (600 ppm, Class 2). The addition ratio employed in the assembly of a macrocyclic or acyclic P1–P3 chain is precisely 1.05 equivalents of the α‑amino‑γ‑lactam propanoate building block relative to the free amine of the quinoxaline‑based P2′ intermediate, using N,N′‑diisopropylcarbodiimide (DIC) and 6‑chloro‑1‑hydroxybenzotriazole (6‑Cl‑HOBt, 1.7 eq) in dimethylformamide at controlled ambient temperature (20 °C – 25 °C). The downstream manufacturing process for the coupled intermediate demands liquid‑phase peptide synthesis (LPPS) executed in jacketed stainless‑steel reactors, with endpoint detection by inline ReactIR monitoring of the isocyanate peak at 2275 cm⁻¹, followed by a biphasic work‑up sequence using 10% w/w aqueous potassium carbonate and 1 N hydrochloric acid to eliminate 6‑Cl‑HOBt byproducts. The terminal dosage form is a film‑coated immediate‑release tablet containing the pan‑genotypic NS3/4A protease inhibitor (e.g., glecaprevir‑class analogue), packaged in cold‑form blister foil to mitigate humidity uptake.

In the synthesis of ¹⁸F‑labeled fibroblast activation protein inhibitors (FAPI) intended for positron emission tomography (PET) imaging of tumor‑associated stroma, the methyl ester terminus of the α‑Boc‑amino‑oxopyrrolidine propanoate precursor is subject to a competitive hydrolysis pathway under the alkaline conditions required for radiofluorination, necessitating strictly anhydrous precursor stock handling. The production of the radiopharmaceutical precursor and the subsequent active pharmaceutical ingredient (API) for clinical imaging falls under the regulatory scopes of USP General Chapter ‹825› (Radiopharmaceuticals—Preparation, Compounding, Dispensing, and Repackaging) and EU GMP Annex 3 (Manufacture of Radiopharmaceuticals). The precursor addition ratio in an automated synthesis module (e.g., GE FASTlab² or Trasis AllinOne) is exactly 12 mg (~28 µmol) of lyophilized precursor trifluoroacetate salt dissolved in anhydrous dimethyl sulfoxide (1.0 mL), dispensed into a dried reaction vessel under positive nitrogen pressure. The downstream radiochemical process consists of azeotropic drying of aqueous [¹⁸F]fluoride with tetra‑n‑butylammonium hydrogen carbonate (TBAHCO₃), followed by nucleophilic substitution at 85 °C for 900 seconds with the precursor. Subsequent Boc acidolysis uses a mixture of trifluoroacetic acid and triisopropylsilane (95:5 v/v) at 40 °C for 300 seconds, and the crude radiotracer is purified by semi‑preparative radio‑RP‑HPLC (Phenomenex Luna C18(2), 10 µm, 250 × 10 mm, gradient elution with 0.1% TFA acetonitrile/water). The finished product type is a single‑dose, sterile, isotonic intravenous solution of an ¹⁸F‑FAPI derivative (e.g., ¹⁸F‑FAPI‑74), with a radiochemical purity exceeding 95% and a total injected activity of 2.5–4.7 MBq/kg body weight, intended for immediate administration in oncology diagnostics.

Process safety boundaries during TFA‑mediated conversion of the Boc‑amino ester to the reactive amine salt

When scaling up the acidolytic removal of the 1,1‑dimethylethoxycarbonyl group from the α‑amino‑substituted 2‑oxopyrrolidine propanoate in kilogram‑scale batch reactors, a critical thermal stability limit is encountered because the nascent aliphatic amine salt can catalyze intramolecular nucleophilic attack on the γ‑lactam carbonyl, leading to ring‑opening and the generation of an undesired 4‑aminobutyric acid derivative impurity above 0.15 area% by HPLC. Forced degradation studies conducted in alignment with ICH Q1A(R2) (Stability Testing of New Drug Substances and Products) define the mandatory quality boundary conditions for this transient intermediate. The optimal cleavage reagent ratio to minimize hydrolysis and lactam opening is a chilled (–15 °C) mixture of trifluoroacetic acid, triisopropylsilane, and anhydrous dichloromethane at a volumetric ratio of 90:5:5 (v/v/v), with a residual water specification set at ≤ 0.03 % w/w as measured by Karl Fischer coulometric titration. Downstream manufacturing must be conducted in a Hastelloy C276‑lined reactor equipped with a PTFE‑coated mechanical stirrer, maintaining a jacket temperature of –10 ± 2 °C and a controlled addition rate of the solid substrate in 5‑gram aliquots over 30 minutes to prevent adiabatic hot‑spot formation. After a total reaction time of precisely 12 minutes, the batch is quenched by transferring into pre‑cooled (–20 °C) methyl tert‑butyl ether under an anhydrous ammonia atmosphere to precipitate the stable amine trifluoroacetate salt, which is subsequently isolated on a Hastelloy pressure filter and dried under a vacuum of ≤ 5 mbar at 25 °C. The output of this controlled conversion is the crystalline monohydrotrifluoroacetate salt of the deprotected (3S,αS)-α‑amino‑2‑oxopyrrolidine propanoate, which is used immediately in downstream amide bond formations to prevent dimerization.

The integration of this specific β‑homoprolinate building block into substance P and neurokinin‑A mimetics targets the metabolic liabilities inherent to the native peptide backbone, particularly the swift cleavage of the Arg‑Gly and Gly‑Leu bonds by neutral endopeptidase (EC 3.4.24.11) observed in systemic circulation. Pre‑clinical development of such neuropeptide analogues follows the non‑clinical safety guidelines stipulated in ICH S7A (Safety Pharmacology Studies for Human Pharmaceuticals) and 21 CFR Part 58 (Good Laboratory Practice for Nonclinical Laboratory Studies). The incorporation of the building block into the peptide chain uses a standard Fmoc/tBu solid‑phase peptide synthesis (SPPS) protocol, where the addition ratio is maintained at 3.0 molar equivalents relative to the free terminal amine of the growing resin‑bound peptide, with activation achieved by 2‑(7‑aza‑1H‑benzotriazole‑1‑yl)‑1,1,3,3‑tetramethyluronium hexafluorophosphate (HATU, 2.9 eq) and N,N‑diisopropylethylamine (DIPEA, 6.0 eq) in N‑methyl‑2‑pyrrolidone, double‑coupled for 45 minutes at 50 °C. The downstream production equipment typically includes an automated microwave‑assisted peptide synthesizer (e.g., CEM Liberty Blue) fitted with a real‑time UV monitoring cell at 301 nm to track Fmoc deprotection and prevent premature truncation sequences. After global cleavage from the Rink‑amide resin with a trifluoroacetic acid:triisopropylsilane:water:dithiothreitol cocktail (92.5:2.5:2.5:2.5 v/v, 3 h, 25 °C), the crude peptide is precipitated from chilled diethyl ether and purified on a preparative C18 column (100 Å, 10 µm, 50 × 250 mm) using a 0.1% TFA water/acetonitrile gradient to deliver the final pharmaceutical form as a lyophilized powder with a net peptide content exceeding 80%. The finished product is a stabilized neuropeptide antagonist, typically a modified substance P analogue, intended as a parenteral injectable for acute neuropathic pain management, thereby bypassing opioidergic mu‑receptor engagement.

When the α‑methyl ester functionality of the pyrrolidinone propanoate must be retained through a Boc‑deprotection step without solvolysis, the separation of the intact non‑ionizable intermediate from the deprotected amine salt poses a significant non‑chromatographic purification hurdle because both species exhibit similar retention in reverse‑phase systems when 0.1 % TFA is used as the sole ion‑pair modifier. Regulatory guidance invoked for this manufacturing intermediate under ICH M10 (Bioanalytical Method Validation and Study Sample Analysis) requires tight control of carryover and interference, measured as the ratio of the blank peak area to the lower limit of quantitation (LLOQ). Empirically, the optimal addition of the Boc‑deprotection reagent (a precooled 4 N HCl in 1,4‑dioxane solution) is adjusted to 5.0 mL per gram of the protected ester, and the solution is stirred at 0 °C for 90 minutes. The downstream manufacturing process shifts from standard RP‑HPLC to a normal‑phase‑like adsorption mechanism driven by hydrophilic interaction liquid chromatography (HILIC), employing a zwitterionic ZIC‑cHILIC column (3 µm, 150 × 4.6 mm) with a mobile phase of ammonium formate (10 mM, pH 3.2) to resolve the neutral ester from its protonated amine derivative with a resolution factor (R_s) greater than 2.5. The final isolated intermediate is the pure (3S,αS)‑free‑amine methyl ester, obtained as a colorless free‑flowing oil after solvent evaporation, with a residual dioxane limit below 380 ppm, which is then telescoped directly into a next‑step ring‑closing metathesis or macrocyclization sequence for the synthesis of large‑ring peptidomimetic conjugation handles used in investigational antibody‑drug conjugate payloads.

Critical chromatographic resolution of the α‑Boc‑methyl propanoate from the N‑demethylated acid impurity

At multi‑gram preparative scale, the purification of the title compound from its N‑demethylated acid congener (the free 2‑oxo‑3‑pyrrolidinepropanoic acid derivative formed by trace esterase activity or chemical hydrolysis during aqueous work‑up) must be addressed using forced‑efficiency dynamic axial compression (DAC) chromatography because traditional batch flash chromatography yields overlapping peak shoulders that compromise the chiral purity necessary for downstream syntheses. The applicable compliance framework for this purification is based on internal ASTM E260 (Standard Practice for Packed Column Gas Chromatography) and USP ‹621› (Chromatography) for system suitability parameters, with specific acceptance criteria for tailing factor (T_f) set between 0.9 and 1.3. The sample loading addition ratio is calibrated at 55 grams of crude ester onto a DAC column packed with 10 µm C18 reverse‑phase silica (5 cm internal diameter, bed length 20 cm), pre‑equilibrated with a mobile phase of acetonitrile and aqueous buffer (25 mM potassium phosphate, pH 3.0) in a 30:70 (v/v) ratio. The manufacturing system is a Novasep Hipersep Lab unit running at a constant flow rate of 80 mL/min, with detection at 210 nm and an operational pressure drop of approximately 45 bar. The 2‑oxopyrrolidine methyl ester fraction pool is subsequently subjected to a continuous‑flow liquid–liquid extraction against dichloromethane to remove the phosphate buffer salts, concentrated under vacuum at ≤ 30 °C, and residual water is reduced to <0.05% by repeated azeotropic distillation with anhydrous toluene. The final finished product form for shipment under cold‑chain (–20 °C) conditions is a highly pure (> 99.7 area%) protected chiral synthon, suitable for use in late‑stage diversification chemistry aiming at clinical candidate optimization without additional purification cycles.